Perrigo Q2 Stock Plunges After Q2 Earnings Miss, Weak Cough/Cold Season

Loading...
Loading...
  • Perrigo Company plc PRGO has posted Q2 sales of $981 million, an increase of 3.4% Y/Y, missing the consensus of $1.02 billion.
  • The sales growth was primarily due to an increase in most businesses and favorable currency movements, partially offset by Y/Y customer inventory reductions and a historically weak cough/cold season. Organic net sales growth was 0.5%.
  • Consumer Self-Care International Segment sales increased 11.7% to $359 million. Organic net sales grew 4.3%.
  • Consumer Self-Care Americas Segment reported sales of $622 million, down 0.9% Y/Y.
  • Adjusted operating income was $118 million, a decrease of 10.7%, due to higher operating expenses primarily to reinstate brand and marketing investments to pre-COVID-19 levels, lower volumes, unfavorable plant overhead absorption, higher input costs.
  • Adjusted diluted EPS of $0.50 declined from $0.59 in the prior-year quarter due primarily to reinstatement of brand and marketing investments. The consensus estimate was $0.62.
  • Outlook: Perrigo reaffirmed fiscal 2021 organic net sales growth outlook of 3% and expected adjusted diluted EPS towards the lower end of guidance of $2.50 - $2.70 (consensus $2.59).
  • Price Action: PRGO shares are down 11.70% at $43.44 on the last check Wednesday.
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsGuidanceShort IdeasHealth CareMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...